A mong the pitfalls that were recognized early in the development of transcatheter aortic valve replacement (TAVR), stroke has been the most concerning. In a meta-analysis, stroke was observed during the first month after the procedure in ≈4% of patients 1 and, in early estimates, is present in as many as 17% of patients after 5 years. 2 A significantly elevated risk of death has been reported in patients who develop stroke after TAVR. 3, 4 Annually, >17 000 patients in Europe and >9000 patients in North America are currently candidates for TAVR. 5 As TAVR use becomes more widespread, recognizing the frequency of stroke and becoming aware of its predictors is likely to be a critical factor aiding patient selection and management, particularly as TAVR becomes applied to lower-risk populations.
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only 344 patients who had undergone TAVR. 6 Analysis of a larger prospective database would allow identification of the stroke risk in various subgroups of patients undergoing TAVR and would also permit more robust identification of the factors that predispose patients to stroke. The US CoreValve investigational program studied the self-expanding CoreValve aortic valve bioprosthesis. The program consisted of 2 randomized clinical trials and a continued access study. Data were collected prospectively in a homogeneous fashion across studies. Accordingly, we sought to identify the risk of neurological events and to identify their predictors in all patients who underwent attempted implantation with the CoreValve bioprosthesis.
Methods

Patients
The design and outcomes of the CoreValve Extreme Risk and High Risk Pivotal Trials have been published previously. 7, 8 The CoreValve Continued Access Study was begun after completion of the pivotal trials and enrolled extreme risk and high risk patients who met the same entry/exclusion criteria as those in the pivotal trials. These studies were approved by the institutional review boards of all participating sites, and all patients provided written informed consent to participate.
Definition and Detection of Stroke
The following algorithm was applied for the diagnosis of stroke. Patients underwent physical examination and evaluation using the National Institutes of Health Stroke Scale (NIHSS) at baseline, ≤24 hours post procedure, at hospital discharge, at 30 days, and then yearly. The NIHSS was administered by an appropriately certified individual (study coordinator or investigator). We report the first score available after the stroke was observed. Definitions of TIA and stroke were concordant with the standardized first Valve Academic Research Consortium consensus document. 6 Neurological events lasting >24 hours or accompanied by concordant imaging abnormalities were classified as strokes. TIA lasted <24 hours and was not accompanied by an imaging abnormality.
Imaging and neurological evaluation were strongly encouraged for all patients who had suspected stroke or TIA, and neurological consultation was obtained in 72.5% of patients with stroke. Stroke severity was graded using the modified Rankin scale (mRS). 9 Values ≥2 were classified as major strokes. All suspected events were adjudicated by a Clinical Events Committee, which included cardiologists, surgeons, and a neurologist. We also evaluated the relationship between site experience and stroke risk.
Statistical Methods
Continuous variables are presented as mean±standard deviation and compared using Student's t test. Categorical data were compared using the χ 2 or Fisher exact test. Event rates for stroke and mortality were estimated using Kaplan-Meier techniques. These rates were compared using the log-rank test. The instantaneous hazard function was estimated from the nonparametric Kaplan-Meier survival function using the Epanechnikov kernel smoothing method with a bandwidth of 10 grid points. Cox proportional hazard models were used for early and late stroke separately. Multivariable predictors of early and late stroke were identified from univariable predictors with P value <0.05. Stepwise multivariable analyses were performed. The significance level thresholds for entry and exit of independent variables were set at 0.10. Sequential models were built based on (1) baseline demographic characteristics, (2) baseline demographic characteristics+baseline imaging characteristics, and (3) baseline demographic characteristics+imaging characteristics+procedural variables. All testings used a 2-sided alpha level of 0.05. Statistical analyses were performed with SAS software, version 9.2 (SAS Institute, Cary, NC).
Results
The studies included 3687 patients who underwent attempted TAVR (followed for a total of 3581 person-years), of whom 174 (4.8%) had a stroke ≤30 days and 270 (8.4%) had a stroke within the first year. The frequencies of major stroke were 2.8% at 30 days and 5.0% at 1 year ( Figure 1 ). The distribution of stroke severity according to the mRS and the NIHSS is shown in Figure 2 ; timing of the assessments is reported in Table I in the Data Supplement. Twenty four (8.9%) strokes were hemorrhagic. Within the first year, 62 (2.1%) patients had had a TIA. The rates of stroke, major stroke, or TIA were not different among the 4 studies (Table  II in the Data Supplement). Among patients suffering a stroke within the first year, 19 (7%) had a second stroke during the first year of follow-up.
The biphasic shape of the hazard function ( Figure 3 ) suggested 2 possible hazard phases for stroke after TAVR. An early phase lasted ≈10 days after the procedure during which time 147 (4.1%) strokes occurred. This period was followed by a later phase that remained constant for the duration of follow-up. There were 123 (4.3%) strokes during this period. Nine (5.2%) patients who had a stroke during the early phase had a second stroke during the late phase. One-year mortality post stroke was nearly identical for patients with a stroke during either phase (46.2% and 44.6% for all strokes) and similar but higher for those patients with a major stroke ( Figure 4 ).
Baseline Characteristics
Patients experiencing early stroke had higher rates of peripheral vascular disease, cerebrovascular disease, angina, and prior TIA. Conversely, these patients had lower rates of prior coronary artery bypass graft, permanent pacemaker, or implantable
WHAT IS KNOWN
• Stroke is a complication of transcatheter aortic valve replacement.
• Stroke occurs with a biphasic frequency after transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• The frequency of stroke is higher than reported in registry studies, probably because of dedicated detection within a clinical trial. This implies that development of new technologies to limit post-transcatheter aortic valve replacement stroke is indeed warranted.
• The predictors of stroke are largely clinical indicators of frailty rather than image-based, implying that further attention toward imaging modalities that can predict the likelihood of stroke and perhaps identify patients at risk of embolization is indicated. Predictors of Neurological Events After TAVR cardioverter defibrillator placement. Patients who had a later stroke were older and had a significantly higher Society of Thoracic Surgeons Predicted Risk of Mortality score ( Table 1 ). Differences in imaging parameters were present only for patients with early stroke and included a lower stroke volume and higher proportion of aortic calcification graded as moderate or greater ( Table III in the Data Supplement). Non-iliofemoral access was used more often in the early stroke patients. Other significant procedural variables in the early stroke group included number of valves implanted, total time in the catheterization laboratory or operating room, total delivery catheter time in the body, rapid pacing during valvuloplasty, and the need for repositioning the CoreValve with a snare ( 
Discharge Medications
Antithrombotic medications at the time of hospital discharge are reported in Table VIII in the Data Supplement. Approximately 95% of patients were discharged on aspirin, 85% were discharged on aspirin with a P2Y12 antagonist, and 61% were discharged on an anticoagulant. The frequency of antithrombotic medications was not different between patients with or without stroke. Among the 24 patients with hemorrhagic stroke, 11 occurred while patients were on aspirin and clopidogrel, 3 occurred while patients were on aspirin and an oral anticoagulant, and 10 occurred while patients were on triple antithrombotic therapy.
Predictors of Stroke
Early Phase
Univariable and multivariable predictors of stroke within 10 days are reported in Table 2 for each of the 3 models. Multivariable predictors were a total NIHSS score >0, manifestations of prior cerebrovascular accident, prior TIA, peripheral vascular disease, absence of prior coronary artery bypass surgery, presence of angina, low body mass index (<21 kg/ m 2 ), and falls within the past 6 months. Significant multivariable procedural predictors were total time in the catheterization laboratory or operating room, total delivery catheter time in the body, rapid pacing during valvuloplasty, and repositioning of the CoreValve with a snare. There were no significant echocardiographic or computerized tomographic angiography (CTA) imaging predictors of early stroke. Noniliofemoral access was of marginal significance (hazard ratio =0.668, 95% confidence interval 0.440-1.014, P=0.06). Multivariable predictors of major stroke were similar (Table 
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IX in the Data Supplement). There were also no significant echocardiographic or CTA imaging predictors of early major stroke.
Clinical site experience did not affect the likelihood of stroke during the early phase. Patients treated within the first 50 cases at each site had an identical stroke rate during to those treated after 50 cases had been completed (4.0% versus 4.0%, hazard ratio =1.003 [95% confidence interval 0.725-1.386]). Similarly, membership in the first tertile of experience within each of the 4 studies did not confer an increased risk of stroke compared with membership in the last tertile (3.5% versus 4.4%, hazard ratio =0.832 [95% confidence interval 0.583-1.187]). 
Discussion
The current study reflects the largest prospectively collected and monitored database of stroke after TAVR, with all suspected strokes adjudicated centrally. The findings reiterate that the frequency of stroke after TAVR is high and does not seem to be mitigated by operator experience and that mortality among patients with stroke is high. Prospective observation for stroke, mandatory NIHSS, and mRS evaluations and a prespecified algorithm for the diagnosis of stroke, as well as extensive site data monitoring, comprise the unique features of this investigation. The rate of stroke observed in this extremely ill population was ≈8.4% at 1 year, whereas the rate of major stroke was 5.0%. These rates seem to be considerably higher than those reported in the US TVT (Transcatheter Valve Therapies) Registry (2.5% at 30 days and 4.1% at 1 year) 10 and the FRANCE-2 registry (French Aortic National CoreValve and Edwards-2) (3.98% at 6 months) and GARY (German Aortic Valve Registry) (1.5% during hospitalization). 11 However, it should be emphasized that the latter registries required self-reporting of events, whereas the current study is drawn from trials that involved mandatory and more rigorous detection of neurological events, central adjudication, study monitoring, and a stricter definition than might be used in standard clinical practice. Additionally, heightened vigilance after the earlier reports of stroke may have increased the detection rate. Multiple reports indicate that approximately three fourths of patients undergoing TAVR are found to have defects on diffusion-weighted magnetic resonance images of the brain or embolic hits on transcranial Doppler. [12] [13] [14] A recent report of experience with an embolic capture device indicated that aortic, valvular, or thrombotic debris were retrieved in 86% of patients. 15 Although it is widely believed that the majority of these findings are not clinically significant in the short and intermediate term, the long-term implications of these events may be more impactful, particularly with respect to cognitive and fine motor disabilities that are not detected with either NIHSS or mRS. In fact, the rates of stroke observed in the current findings, particularly the rate of 4% within the first 10 days, suggest that perhaps more embolic events are significant than previously believed.
Two major similarities to previous reports are present. Like the PARTNER investigators, we confirmed the high mortality among patients who had stroke. Nearly 50% of patients who had a stroke in the first PARTNER Trials had died by the end of the first year compared with fewer than 20% who did not have a stroke. Mortality after major stroke was only modestly higher than that for all stroke, although it is possible that this difference will continue to widen as data are collected over subsequent years. In addition, like other investigators, 6, [16] [17] [18] [19] we also observed a biphasic frequency of stroke, with slightly more than half occurring within the first 10 days after TAVR. These events are likely to reflect periprocedural occurrences. Their exact timing may reflect their ascertainment related to patient recovery from sedation or anesthesia during TAVR, as well as the timing of study-related neurological assessments.
As expected, predictors of early stroke included demographic features, indicating the degree of illness of the patients as well as procedural factors mostly related to the duration and complexity of the procedure, whereas predictors of stroke after the early phase were confined to indicators of frailty and to the presence of aortic calcification, which was likely an indicator of risk for aorto-arterial embolic events. Unlike other authors, 16, 20 we did not observe either aortic valve area or balloon postdilation of the TAVR prosthesis to be predictors of stroke. This finding may be related to different designs among valves studied. Specifically, the large frame surrounding the CoreValve prosthesis may limit the propensity of particles to embolize from the wall of the ascending aorta. Alternatively, it may reflect different clinical decision thresholds in postdilating a self-expanding versus a balloon expandable valve. Balloon valvuloplasty after implantation was performed in 23.1% of patients in the current study and in 12.4% of patients reported by Hahn, 20 raising the possibility that in the latter studies, patients who underwent postdilation had more extensive vascular disease.
Unlike Nombela-Franco et al, 16 we were unable to detect a learning curve effect on the frequency of stroke. Additionally, neither the timing of the trials (Pivotal versus Continued Access) nor procedures among the first 50 cases at each site nor membership within the first tertile of experience were associated with higher stroke risk. Although the latter study encompasses the early stages of TAVR, our observations may reflect implementation of lessons learned from the early TAVR experience before implementation of the CoreValve clinical CI indicates confidence interval. Predictors of Neurological Events After TAVR studies or alternatively may be because of the rigorous review of potential cases by the clinical review committees and of the strict proctoring requirements of the studies. These findings must be interpreted cautiously because sites were allowed to add new operators after the first 50 cases had been completed, and new sites were added at varying points along the course of the studies. Alternatively, given the close scrutiny to which patients in these studies were subjected, the lack of a relationship between site or operator experience may suggest that the instrumentation of the aorta, arch, and valvular structures that are requisite for TAVR is associated with a risk that is not modifiable by experience. Interestingly, classical predictors of stroke risk, including hypertension and hyperlipidemia, did not predict either early or late stroke risk, most likely a result of follow-up only to 1 year. Neither congestive heart failure nor atrial fibrillation (either at any time during the follow-up or within the first postprocedural day) predicted stroke risk, despite the generally high attributable risk that is usually associated with them in elderly patients. 21 Although these associations cannot be definitively excluded, factors peculiar to the investigation may potentially obscure the ability to detect such an association: the limited duration of the follow-up period, the study requirement for patients to be on aspirin and clopidogrel, the possibility that many who had atrial fibrillation were already on oral anticoagulants, and the relatively short telemetric monitoring period after the TAVR procedure.
Another interesting and previously unreported observation in this study is the seemingly high proportion of patients who had clinical strokes but who had low NIHSS and mRS scores (Figure 2 ). This finding is in excess of the rates that have been reported in dedicated stroke trials. Although it may reflect delays between the diagnosis of stroke and the protocol-mandated NIHSS determination, as well as limited sensitivity of these scales, it is interesting to speculate that it also indicates that in some patients who meet technical definitions for stroke, the mechanism for post-TAVR stroke, in particular microembolization of debris, may afford an opportunity for recovery of cerebral function. Obviously, further replication of this observation will be required.
Finally, the number of patients with hemorrhagic stroke was small. However, the observation that nearly half of these events occurred while patients were on triple antithrombotic therapy reiterates previous observations of the hemorrhagic risk associated with triple antithrombotic therapy. 22, 23 A recent report using 4-dimensional computerized tomographic imaging of bioprosthetic aortic valves revealed previously unsuspected thrombosis at the site of the valve leaflets and indicated an elevated risk of stroke in such patients. 24 Four-dimensional scanning was not performed in the current cohort of patients. Although these findings suggest that more aggressive antithrombotic treatment might be indicated to reduce the risk of stroke, the current findings that nearly half the hemorrhagic strokes were associated with triple antithrombotic therapy clearly imply that such strategies will need to be investigated carefully in the predominantly elderly and frail population that undergoes TAVR.
Limitations
Although the patient population studied in this analysis was well characterized clinically and was subjected to careful periprocedural imaging, more extensive characterization of calcification within the aortic arch and ascending aorta, perhaps by computed tomographic angiography or by mandatory transesophageal echocardiography, might have provided the ability to identify specific morphological details that might have been powerful predictors of stroke during the early period. Additionally, mandatory telemetric monitoring during the entire period of hospitalization or perhaps implantation of remote monitoring devices might have provided a more robust estimate of the prevalence, duration, and contribution to stroke risk of atrial fibrillation in this elderly population with a high frequency of heart failure.
Implications
The current data indicate that the rate of stroke after TAVR remains a significant concern. The striking difference between the rates reported in this compendium of clinical trials that used rigorous ascertainment procedures and those reported in large registries suggest that further efforts to limit stroke, such as embolic protection devices and new antithrombotic regimens, merit investigation. In addition, the observation that readily available imaging data did not contribute to the ability to predict stroke is disappointing. It suggests that further advances in imaging, specifically refinement of techniques that can more precisely characterize anatomic features that predispose patients to stroke, are indicated.
